Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q2 EPS by 5c; Guides FY11
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $225.92 +0.56%
Revenue Growth %: +6.2%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +6.2%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q2 EPS of $0.82, $0.05 better than the analyst estimate of $0.77. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $61.86 million.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- Jazz Pharmaceuticals presents Xywav sleep disorder data at SLEEP 2026 conference
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
